Immitra Bio has secured CHF 2.4 million to develop gene-editing treatments, comprising CHF 2.25 million from investors and CHF 150,000 in non-dilutive funding. Backbone Ventures led the financing with OCCIDENT as co-lead. The ETH spin-off has research laboratories in Schlieren and its headquarters in Geneva.
The money will support preclinical studies of IB-003, its lead candidate for an inherited anaemia. Rather than removing, editing and transplanting a patient's stem cells, the company is developing a treatment that edits cells inside the body. Its aim is an off-the-shelf therapy that works across different mutations causing the same disease, without chemotherapy or individual cell manufacturing; the financing supports testing this approach, not a treatment already available to patients.
